SG10201909675QA - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents
Peptide vaccines for cancers expressing tumor-associated antigensInfo
- Publication number
- SG10201909675QA SG10201909675QA SG10201909675QA SG10201909675QA SG 10201909675Q A SG10201909675Q A SG 10201909675QA SG 10201909675Q A SG10201909675Q A SG 10201909675QA SG 10201909675Q A SG10201909675Q A SG 10201909675QA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- present
- expressing tumor
- associated antigens
- peptide vaccines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 229940023041 peptide vaccine Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102100024153 Cadherin-15 Human genes 0.000 abstract 1
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 abstract 1
- 101150078651 Epha4 gene Proteins 0.000 abstract 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 abstract 1
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 abstract 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 abstract 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 abstract 1
- 101000839066 Homo sapiens Hypoxia-inducible lipid droplet-associated protein Proteins 0.000 abstract 1
- 101001054725 Homo sapiens Inhibin beta B chain Proteins 0.000 abstract 1
- 101001027621 Homo sapiens Kinesin-like protein KIF20A Proteins 0.000 abstract 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 abstract 1
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 abstract 1
- 102100028891 Hypoxia-inducible lipid droplet-associated protein Human genes 0.000 abstract 1
- 102100027003 Inhibin beta B chain Human genes 0.000 abstract 1
- 102100037694 Kinesin-like protein KIF20A Human genes 0.000 abstract 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 abstract 1
- 102100040437 Protein ECT2 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR- ASSOCIATED ANTIGENS The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines. (NO SUITABLE FIGURE)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90294907P | 2007-02-21 | 2007-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201909675QA true SG10201909675QA (en) | 2019-11-28 |
Family
ID=39709837
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012012126A SG179402A1 (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
SG10201506589WA SG10201506589WA (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
SG10201909675Q SG10201909675QA (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012012126A SG179402A1 (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
SG10201506589WA SG10201506589WA (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
Country Status (28)
Country | Link |
---|---|
EP (20) | EP2476695A3 (en) |
JP (6) | JP5239103B2 (en) |
KR (8) | KR101540000B1 (en) |
CN (4) | CN101663315B (en) |
AR (1) | AR068302A1 (en) |
AU (1) | AU2008218463B2 (en) |
BR (1) | BRPI0808421B1 (en) |
CA (3) | CA2992074C (en) |
CO (1) | CO6190536A2 (en) |
CY (2) | CY1114590T1 (en) |
DK (3) | DK2465864T3 (en) |
ES (6) | ES2541863T3 (en) |
HK (7) | HK1134507A1 (en) |
HR (3) | HRP20131044T1 (en) |
IL (10) | IL200478A (en) |
MX (4) | MX2009009022A (en) |
MY (2) | MY173379A (en) |
NZ (4) | NZ591704A (en) |
PH (1) | PH12014501642B1 (en) |
PL (3) | PL2476694T3 (en) |
PT (2) | PT2121731E (en) |
RU (1) | RU2464275C2 (en) |
SG (3) | SG179402A1 (en) |
SI (3) | SI2465864T1 (en) |
TW (5) | TWI438207B (en) |
UA (1) | UA100372C2 (en) |
WO (1) | WO2008102557A1 (en) |
ZA (1) | ZA200905881B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4614952B2 (en) | 2003-08-20 | 2011-01-19 | オンコセラピー・サイエンス株式会社 | Hypoxia-inducible protein 2 (HIG2) as a potential new therapeutic target for renal cell carcinoma (RCC) |
MX2010002018A (en) | 2007-08-20 | 2010-05-27 | Oncotherapy Science Inc | Cdh3 peptide and medicinal agent comprising the same. |
JP5593560B2 (en) | 2008-06-30 | 2014-09-24 | オンコセラピー・サイエンス株式会社 | Anti-CDH3 antibody labeled with radioisotope label and use thereof |
TWI580431B (en) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Hig2 and urlc10 epitope peptide and vaccines containing the same |
TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
CN102264897B (en) * | 2008-10-22 | 2014-06-11 | 肿瘤疗法科学股份有限公司 | Rab6kifl/kif20a epitope peptide and vaccines containing the same |
TWI539160B (en) * | 2008-12-05 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Wdrpuh epitope peptides and vaccines containing the same |
BRPI0923402A2 (en) * | 2008-12-24 | 2015-08-04 | Oncotherapy Science Inc | C10rf59 peptides and vaccines including the same. |
TW201102081A (en) * | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
EP2519542B1 (en) | 2009-12-28 | 2018-10-10 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
EP2547359B1 (en) | 2010-03-15 | 2016-03-09 | The Board of Trustees of the University of Illionis | Inhibitors of beta integrin-g protein alpha subunit binding interactions |
TW201627003A (en) * | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | ECT2 peptides and vaccines including the same |
DK2646546T3 (en) * | 2010-12-02 | 2018-08-06 | Oncotherapy Science Inc | TOMM34 PEPTIDES AND VACCINES CONTAINING THESE |
JP6820653B2 (en) * | 2011-12-14 | 2021-01-27 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Secondary gene inactivation biomarkers and targets for cancer treatment |
US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
US9561265B2 (en) | 2012-07-10 | 2017-02-07 | Oncotherapy Science, Inc. | KIF20A epitope peptides for TH1 cells and vaccines containing the same |
JP6255594B2 (en) * | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | LY6K epitope peptide of Th1 cell and vaccine containing the same |
EP2891663B8 (en) | 2012-08-31 | 2018-04-04 | Vasculead Inc. | Psf1-derived peptide |
CN107881158B (en) | 2012-09-11 | 2021-11-16 | 肿瘤疗法科学股份有限公司 | UBE2T peptides and vaccines containing the same |
WO2014141652A1 (en) * | 2013-03-11 | 2014-09-18 | Oncotherapy Science, Inc. | Smyd3 peptides and vaccines containing the same |
TWI658049B (en) * | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Kntc2 peptides and vaccines containing the same |
AU2014288127A1 (en) * | 2013-07-12 | 2016-02-18 | Sapporo Medical University | Tumor antigen peptide |
JP2015227292A (en) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | Pancreatic cancer cell invasion metastasis inhibition vaccine |
BR112016030740A2 (en) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | bispecific heterodimeric bodies and their uses |
RU2700881C2 (en) * | 2014-08-04 | 2019-09-23 | Онкотерапи Сайенс, Инк. | Urlc10-derived peptide and vaccine containing same |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
CN104975082B (en) * | 2015-06-05 | 2018-11-02 | 复旦大学附属肿瘤医院 | One group of gene and its application for assessing lung cancer for prognosis |
WO2018090257A1 (en) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | Polypeptide and application thereof |
PT3573600T (en) | 2017-01-25 | 2022-05-11 | Ose Immunotherapeutics | Method for manufacturing a stable emulsion for peptide delivery |
WO2018183447A1 (en) * | 2017-03-28 | 2018-10-04 | Zhenglun Zhu | Methods of treating neoplastic diseases |
WO2019031939A2 (en) * | 2017-08-10 | 2019-02-14 | 주식회사 굳티셀 | Method for activating t cells for cancer treatment |
US20210038703A1 (en) * | 2018-02-15 | 2021-02-11 | National University Corporation Asahikawa Medical University | Cancer Antigen Peptide |
KR102322832B1 (en) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | Human leukocyte antigen A24:02 allele specific binding peptides and uses thereof |
KR102335916B1 (en) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | Human leukocyte antigen A02:01 allele specific binding peptides and uses thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
NZ231899A (en) * | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2084180A1 (en) * | 1991-12-11 | 1993-06-12 | Paul P. Hung | Expression of specific immunogens using viral antigens |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
EP1464706A3 (en) * | 1994-04-15 | 2004-11-03 | Amgen Inc., | HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
EP0841945B1 (en) | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
AU6795898A (en) * | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
FR2766205B1 (en) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD |
EP1627886A1 (en) * | 1997-10-07 | 2006-02-22 | Ono Pharmaceutical Co., Ltd. | Polypeptide, cDNA encoding the same, and use of them |
US20070014787A1 (en) * | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
WO2001029221A2 (en) * | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Proteins and polynucleotides encoding them |
US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
CN1469926A (en) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | Compositions and methods for the therapy and diagnosis of lung cancer |
AU2001278070A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Basal cell markers in breast cancer and uses thereof |
US6830885B1 (en) * | 2000-08-18 | 2004-12-14 | Phenogene Therapeutiques Inc. | Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature |
US20090062512A1 (en) * | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
CN100400099C (en) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | Recombinant protein vaccine for preventing and treating human prostata cancer |
AU2002311787A1 (en) * | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002086443A2 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
AU2002347428A1 (en) * | 2001-06-18 | 2003-01-02 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
CN1653080A (en) * | 2002-03-07 | 2005-08-10 | 路德维格癌症研究院 | Lymphatic and blood endothelial cell genes |
US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
JP2007527193A (en) * | 2002-12-10 | 2007-09-27 | アンドキューブ ソシエタ パー アクシオン シンプリフィー | THAP protein as a nuclear receptor for chemokines and its role in transcriptional regulation, cell proliferation, and cell differentiation |
JP2006517788A (en) * | 2002-12-20 | 2006-08-03 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 1421 , Methods and compositions for treating cancer using the 33877,10317,10485,25964,14815,1363,1397,14827,21708,3801,64698,2179 or 13249 |
TWI324608B (en) * | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
EP1651775A2 (en) * | 2003-06-18 | 2006-05-03 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
JP4614952B2 (en) * | 2003-08-20 | 2011-01-19 | オンコセラピー・サイエンス株式会社 | Hypoxia-inducible protein 2 (HIG2) as a potential new therapeutic target for renal cell carcinoma (RCC) |
US20070253954A1 (en) * | 2004-02-27 | 2007-11-01 | Oncotherapy Science, Inc. | Epha4 As Therapeutic Target Of Prc And Pdaca |
JP4761389B2 (en) * | 2004-04-09 | 2011-08-31 | 株式会社ジーンケア研究所 | Cancer cell-specific apoptosis inducer targeting genes related to chromosome stabilization |
EP1756147A2 (en) * | 2004-06-01 | 2007-02-28 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
US7915036B2 (en) | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
CN100381460C (en) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | HER-2 analogue antigen epitope and peptide containing said epitope |
US20090075832A1 (en) * | 2005-02-24 | 2009-03-19 | Cemines, Inc | Compositions and Methods for Classifying Biological Samples |
PT2325305E (en) * | 2005-02-25 | 2014-04-29 | Oncotherapy Science Inc | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides |
CN100348614C (en) * | 2005-06-03 | 2007-11-14 | 北京大学 | Idiosyncratic antigen protein, and antigen peptide of liver cancer orchis pellet |
CN101313063B (en) * | 2005-08-09 | 2013-04-03 | 肿瘤疗法·科学股份有限公司 | Cancer-rejection antigen peptide derived from glypican-3 (GPC3) for use in HLA-A2-positive patient and pharmaceutical comprising the antigen |
EP1930427B1 (en) * | 2005-08-09 | 2012-04-11 | Kurume University | Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule |
US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
WO2007064743A2 (en) * | 2005-11-30 | 2007-06-07 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
JP5290148B2 (en) * | 2006-04-10 | 2013-09-18 | ジェネンテック, インコーポレイテッド | Disheveled (Dvl) PDZ modifier |
MX2008015939A (en) * | 2006-06-16 | 2009-02-11 | Univ Kumamoto | Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same. |
EP1972639A3 (en) * | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
MX2010002018A (en) * | 2007-08-20 | 2010-05-27 | Oncotherapy Science Inc | Cdh3 peptide and medicinal agent comprising the same. |
EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
TWI580431B (en) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Hig2 and urlc10 epitope peptide and vaccines containing the same |
WO2011039289A1 (en) * | 2009-09-29 | 2011-04-07 | Protagen Ag | Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof |
-
2008
- 2008-02-18 TW TW097105594A patent/TWI438207B/en not_active IP Right Cessation
- 2008-02-18 TW TW105108412A patent/TWI615403B/en active
- 2008-02-18 TW TW104120673A patent/TWI596109B/en not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/en active
- 2008-02-18 TW TW103114624A patent/TWI494319B/en not_active IP Right Cessation
- 2008-02-21 PL PL12151717T patent/PL2476694T3/en unknown
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 NZ NZ591704A patent/NZ591704A/en not_active IP Right Cessation
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/en active IP Right Grant
- 2008-02-21 PL PL12151711T patent/PL2465864T3/en unknown
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/en active IP Right Grant
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/en active Active
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/en active IP Right Grant
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 MX MX2013009906A patent/MX337417B/en unknown
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/en active IP Right Grant
- 2008-02-21 MX MX2013009905A patent/MX337456B/en unknown
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 SI SI200831332T patent/SI2465864T1/en unknown
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/en not_active IP Right Cessation
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/en active Active
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/en active Active
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 SI SI200831053T patent/SI2121731T1/en unknown
- 2008-02-21 MX MX2016002567A patent/MX359680B/en unknown
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/en active IP Right Grant
- 2008-02-21 PT PT87104436T patent/PT2121731E/en unknown
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/en active Active
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/en active IP Right Grant
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 AR ARP080100718A patent/AR068302A1/en unknown
- 2008-02-21 PL PL08710443T patent/PL2121731T3/en unknown
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/en active IP Right Grant
- 2008-02-21 ES ES08710443T patent/ES2435194T3/en active Active
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 SI SI200831368T patent/SI2476694T1/en unknown
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/en active Active
- 2008-02-21 PT PT121517114T patent/PT2465864E/en unknown
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/en active Active
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/en active Active
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/en active IP Right Grant
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en active Active
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/en active Active
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 ES ES12151717T patent/ES2530777T3/en active Active
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/en active Active
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/en not_active Application Discontinuation
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/en active
- 2008-02-21 UA UAA200909469A patent/UA100372C2/en unknown
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/en active
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en active Application Filing
-
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/en unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/en not_active Application Discontinuation
-
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/en active Active
- 2010-03-10 HK HK10102517.8A patent/HK1134507A1/en not_active IP Right Cessation
- 2010-03-10 HK HK12112897.5A patent/HK1172041A1/en not_active IP Right Cessation
- 2010-03-10 HK HK12112988.5A patent/HK1172345A1/en not_active IP Right Cessation
- 2010-03-10 HK HK12112987.6A patent/HK1172344A1/en not_active IP Right Cessation
- 2010-03-10 HK HK12112898.4A patent/HK1172042A1/en not_active IP Right Cessation
- 2010-03-10 HK HK12112989A patent/HK1172346A1/en not_active IP Right Cessation
- 2010-03-10 HK HK12112899.3A patent/HK1172043A1/en not_active IP Right Cessation
-
2012
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/en active Active
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/en active Active
-
2013
- 2013-11-05 HR HRP20131044AT patent/HRP20131044T1/en unknown
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/en unknown
-
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642B1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/en not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/en unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/en unknown
-
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/en unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501642A1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
MX2009004147A (en) | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides. | |
WO2006090810A3 (en) | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides | |
DE602007011901D1 (en) | PTIDES AND CELL PENETRATING PEPTIDES COUPLED A | |
UA100127C2 (en) | Peptide cdh3 and drug containing it | |
SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
MX2009007261A (en) | Foxp3 peptide vaccine. | |
NZ592461A (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same | |
MX2010005816A (en) | Stat3 epitope peptides. | |
EP4047009A3 (en) | Wdrpuh epitope peptides and vaccines containing the same | |
TH120970B (en) | Peptide vaccine for antigens involved in malignant tumors. | |
TH120970A (en) | Peptide vaccine for antigens involved in malignant tumors. |